Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin (Q37162872)

18 August 2017

1 reference

title

Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin (English)

1 reference

methicillin-resistant Staphylococcus aureus

18 August 2017

main subject

0 references

Staphylococcus aureus

1 reference

Shawn D Anderson

1

1 reference

18 August 2017

John G Gums

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

13 May 2008

1 reference

Annals of Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

42

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

806-816

1 reference

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

18 August 2017

cites work

1 reference

In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Can beta-lactams be re-engineered to beat MRSA?

21 January 2018

1 reference

Molecular aspects of methicillin resistance in Staphylococcus aureus

21 January 2018

1 reference

Solving staphylococcal resistance to β-lactams

21 January 2018

1 reference

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae

21 January 2018

1 reference

Penicillin-binding proteins and bacterial resistance to beta-lactams

21 January 2018

1 reference

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

21 January 2018

1 reference

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes

21 January 2018

1 reference

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

21 January 2018

1 reference

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci

21 January 2018

1 reference

Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees

21 January 2018

1 reference

Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis

21 January 2018

1 reference

Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

21 January 2018

1 reference

Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

21 January 2018

1 reference

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates

21 January 2018

1 reference

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

21 January 2018

1 reference

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria

21 January 2018

1 reference

In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters

21 January 2018

1 reference

Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis

21 January 2018

1 reference

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections

21 January 2018

1 reference

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity

21 January 2018

1 reference

Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms

21 January 2018

1 reference

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects

21 January 2018

1 reference

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

21 January 2018

1 reference

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L016

1 reference

18 August 2017

1 reference